Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features | Lung Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Bray  F, Ferlay  J, Soerjomataram  I, Siegel  RL, Torre  LA, Jemal  A.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.   CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492PubMedGoogle ScholarCrossref
2.
Fedor  D, Johnson  WR, Singhal  S.  Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes.   Surg Oncol. 2013;22(3):156-161. doi:10.1016/j.suronc.2013.04.002 PubMedGoogle ScholarCrossref
3.
Brierley  JD, Gospodarowicz  MK, Wittekind  C, eds.  TNM Classification of Malignant Tumours. 8th ed. Wiley-Blackwell; 2017.
4.
Pignon  J-P, Tribodet  H, Scagliotti  GV,  et al; LACE Collaborative Group.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.   J Clin Oncol. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030 PubMedGoogle ScholarCrossref
5.
Arriagada  R, Auperin  A, Burdett  S,  et al; NSCLC Meta-analyses Collaborative Group.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.   Lancet. 2010;375(9722):1267-1277. doi:10.1016/S0140-6736(10)60059-1 PubMedGoogle ScholarCrossref
6.
Douillard  J-Y, Rosell  R, De Lena  M,  et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.   Lancet Oncol. 2006;7(9):719-727. doi:10.1016/S1470-2045(06)70804-X PubMedGoogle ScholarCrossref
7.
Arriagada  R, Bergman  B, Dunant  A, Le Chevalier  T, Pignon  JP, Vansteenkiste  J; International Adjuvant Lung Cancer Trial Collaborative Group.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.   N Engl J Med. 2004;350(4):351-360. doi:10.1056/NEJMoa031644 PubMedGoogle ScholarCrossref
8.
Winton  T, Livingston  R, Johnson  D,  et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.   N Engl J Med. 2005;352(25):2589-2597. doi:10.1056/NEJMoa043623 PubMedGoogle ScholarCrossref
9.
Waller  D, Peake  MD, Stephens  RJ,  et al.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.   Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 PubMedGoogle ScholarCrossref
10.
Scagliotti  GV, Fossati  R, Torri  V,  et al; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer.   J Natl Cancer Inst. 2003;95(19):1453-1461. doi:10.1093/jnci/djg059 PubMedGoogle ScholarCrossref
11.
Strauss  GM, Herndon  JE  II, Maddaus  MA,  et al.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.   J Clin Oncol. 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.4855 PubMedGoogle ScholarCrossref
12.
Kris  MG, Gaspar  LE, Chaft  JE,  et al.  Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update.   J Clin Oncol. 2017;35(25):2960-2974. doi:10.1200/JCO.2017.72.4401 PubMedGoogle ScholarCrossref
13.
Postmus  PE, Kerr  KM, Oudkerk  M,  et al; ESMO Guidelines Committee.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up.   Ann Oncol. 2017;28(suppl 4):iv1-iv21. doi:10.1093/annonc/mdx222Google ScholarCrossref
14.
National Comprehensive Cancer Network. Non-small cell lung cancer. Version 3.2020. Accessed March 1, 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
15.
Mallin  K, Browner  A, Palis  B,  et al.  Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012-2014.   Ann Surg Oncol. 2019;26(6):1604-1612. doi:10.1245/s10434-019-07213-1 PubMedGoogle ScholarCrossref
16.
Boffa  DJ, Rosen  JE, Mallin  K,  et al.  Using the National Cancer Database for outcomes research: a review.   JAMA Oncol. 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905 PubMedGoogle ScholarCrossref
17.
American College of Surgeons. Welcome to the 2016 PUF Data Dictionary. Accessed January 1, 2020. http://ncdbpuf.facs.org
18.
Amin  MB, Gress  DM, Vega  LRM,  et al.  AJCC Cancer Staging Manual. 8th ed. Springer; 2018.
19.
Edge  S, Byrd  DR, Compton  CC, Fritz  AG, Greene  FL, Trotti  A.  AJCC Cancer Staging Manual. 7th ed. Springer; 2011.
20.
Sterne  JAC, White  IR, Carlin  JB,  et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.   BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393 PubMedGoogle ScholarCrossref
21.
Rubin  DB.  Multiple Imputation for Nonresponse in Surveys. Wiley-Interscience; 2004.
22.
Heinze  G, Wallisch  C, Dunkler  D.  Variable selection—a review and recommendations for the practicing statistician.   Biom J. 2018;60(3):431-449. doi:10.1002/bimj.201700067 PubMedGoogle ScholarCrossref
23.
Panageas  KS, Schrag  D, Riedel  E, Bach  PB, Begg  CB.  The effect of clustering of outcomes on the association of procedure volume and surgical outcomes.   Ann Intern Med. 2003;139(8):658-665. doi:10.7326/0003-4819-139-8-200310210-00009 PubMedGoogle ScholarCrossref
24.
Bellera  CA, MacGrogan  G, Debled  M, de Lara  CT, Brouste  V, Mathoulin-Pélissier  S.  Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer.   BMC Med Res Methodol. 2010;10:20. doi:10.1186/1471-2288-10-20 PubMedGoogle ScholarCrossref
25.
Austin  PC, Stuart  EA.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.   Stat Med. 2015;34(28):3661-3679. doi:10.1002/sim.6607PubMedGoogle ScholarCrossref
26.
Park  SY, Lee  JG, Kim  J,  et al.  Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.   J Cardiothorac Surg. 2013;8:151. doi:10.1186/1749-8090-8-151 PubMedGoogle ScholarCrossref
27.
Jiang  L, Liang  W, Shen  J,  et al.  The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis.   Chest. 2015;148(4):903-911. doi:10.1378/chest.14-2765 PubMedGoogle ScholarCrossref
28.
Morgensztern  D, Du  L, Waqar  SN,  et al.  Adjuvant chemotherapy for patients with T2N0M0 NSCLC.   J Thorac Oncol. 2016;11(10):1729-1735. doi:10.1016/j.jtho.2016.05.022 PubMedGoogle ScholarCrossref
29.
Tsutani  Y, Imai  K, Ito  H,  et al.  Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: a multicenter study.   J Clin Oncol. 2019;37(15, suppl):8500. doi:10.1200/JCO.2019.37.15_suppl.8500Google ScholarCrossref
30.
Langer  CJ, Moughan  J, Movsas  B,  et al.  Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?   Lung Cancer. 2005;48(1):93-102. doi:10.1016/j.lungcan.2004.09.005 PubMedGoogle ScholarCrossref
31.
Stinchcombe  TE, Detterbeck  FC, Lin  L, Rivera  MP, Socinski  MA.  Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer.   J Thorac Oncol. 2007;2(9):819-826. doi:10.1097/JTO.0b013e31811f478a PubMedGoogle ScholarCrossref
32.
Park  HJ, Park  HS, Cha  YJ,  et al.  Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study.   J Thorac Dis. 2018;10(4):2279-2287. doi:10.21037/jtd.2018.03.184 PubMedGoogle ScholarCrossref
33.
Li  X, Zhang  C, Sun  Z,  et al.  Propensity-matched analysis of adjuvant chemotherapy for completely resected stage IB non-small-cell lung cancer patients.   Lung Cancer. 2019;133:75-82. doi:10.1016/j.lungcan.2019.04.024 PubMedGoogle ScholarCrossref
34.
Wang  J, Wu  N, Lv  C, Yan  S, Yang  Y. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? a comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients. J Cancer Res Clin Oncol. 2019;145(2):463-469.
35.
Roselli  M, Mariotti  S, Ferroni  P,  et al.  Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study.   Int J Cancer. 2006;119(4):955-960. doi:10.1002/ijc.21933 PubMedGoogle ScholarCrossref
36.
Khullar  OV, Liu  Y, Gillespie  T,  et al.  Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer: an analysis from the National Cancer Data Base.   J Thorac Oncol. 2015;10(11):1625-1633. doi:10.1097/JTO.0000000000000664 PubMedGoogle ScholarCrossref
37.
Veluswamy  RR, Mhango  G, Bonomi  M,  et al.  Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.   Ann Am Thorac Soc. 2013;10(6):622-628. doi:10.1513/AnnalsATS.201305-127OC PubMedGoogle ScholarCrossref
38.
Ginsberg  RJ, Rubinstein  LV; Lung Cancer Study Group.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer.   Ann Thorac Surg. 1995;60(3):615-622. doi:10.1016/0003-4975(95)00537-U PubMedGoogle ScholarCrossref
39.
Yendamuri  S, Sharma  R, Demmy  M,  et al.  Temporal trends in outcomes following sublobar and lobar resections for small (≤2 cm) non-small cell lung cancers—a Surveillance Epidemiology End Results database analysis.   J Surg Res. 2013;183(1):27-32. doi:10.1016/j.jss.2012.11.052 PubMedGoogle ScholarCrossref
40.
Cao  C, Gupta  S, Chandrakumar  D, Tian  DH, Black  D, Yan  TD.  Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer.   Ann Cardiothorac Surg. 2014;3(2):134-141.PubMedGoogle Scholar
41.
Okada  M, Koike  T, Higashiyama  M, Yamato  Y, Kodama  K, Tsubota  N.  Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study.   J Thorac Cardiovasc Surg. 2006;132(4):769-775. doi:10.1016/j.jtcvs.2006.02.063 PubMedGoogle ScholarCrossref
42.
Altorki  NK, Wang  X, Wigle  D,  et al.  Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).   Lancet Respir Med. 2018;6(12):915-924. doi:10.1016/S2213-2600(18)30411-9 PubMedGoogle ScholarCrossref
43.
Speicher  PJ, Gu  L, Gulack  BC,  et al.  Sublobar resection for clinical stage IA non-small-cell lung cancer in the United States.   Clin Lung Cancer. 2016;17(1):47-55. doi:10.1016/j.cllc.2015.07.005 PubMedGoogle ScholarCrossref
44.
Arora  RK, Gibson  AW, Bebb  DG, Cheung  WY.  The population-based impact of adjuvant chemotherapy on outcomes in T2N0M0 non-small cell lung cancer.   Am J Clin Oncol. 2020;43(7):496-503. doi:10.1097/COC.0000000000000694PubMedGoogle ScholarCrossref
45.
Ahmad  U, Crabtree  TD, Patel  AP,  et al.  Adjuvant chemotherapy is associated with improved survival in locally invasive node negative non-small cell lung cancer.   Ann Thorac Surg. 2017;104(1):303-307. doi:10.1016/j.athoracsur.2017.01.069PubMedGoogle ScholarCrossref
46.
Dziedzic  R, Zurek  W, Marjanski  T,  et al.  Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry.   Eur J Cardiothorac Surg. 2017;52(2):363-369. doi:10.1093/ejcts/ezx092 PubMedGoogle ScholarCrossref
47.
Bedetti  B, Bertolaccini  L, Rocco  R, Schmidt  J, Solli  P, Scarci  M.  Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis.   J Thorac Dis. 2017;9(6):1615-1623. doi:10.21037/jtd.2017.05.79 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    September 17, 2020

    Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

    Author Affiliations
    • 1Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut
    • 2Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut
    • 3Array Biostatistics, Wilmington, North Carolina
    • 4Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut
    JAMA Oncol. 2020;6(11):1741-1750. doi:10.1001/jamaoncol.2020.4232
    Key Points

    Question  Is adjuvant chemotherapy associated with survival in patients with node-negative, early-stage non–small cell lung cancer (NSCLC) with vs without high-risk clinicopathologic features?

    Findings  In this cohort study of 50 814 patients with NSCLC, adjuvant chemotherapy use was associated with a survival benefit if the tumor was larger than 3 to 4 cm and sublobar resection was performed, the tumor was larger than 4 to 5 cm and at least 1 high-risk pathologic feature was present, or the tumor was larger than 5 cm irrespective of high-risk pathologic features.

    Meaning  The findings suggest that high-risk pathologic features, extent of resection, and tumor size should be simultaneously considered when evaluating patients with early-stage NSCLC for adjuvant chemotherapy.

    Abstract

    Importance  Tumor size larger than 4 cm is accepted as an indication for adjuvant chemotherapy in patients with node-negative non–small cell lung cancer (NSCLC). Treatment guidelines suggest that high-risk features are also associated with the efficacy of adjuvant chemotherapy among patients with early-stage NSCLC, yet this association is understudied.

    Objective  To assess the association between adjuvant chemotherapy and survival in the presence and absence of high-risk pathologic features in patients with node-negative early-stage NSCLC.

    Design, Setting, and Participants  This retrospective cohort study using data from the National Cancer Database included 50 814 treatment-naive patients with a completely resected node-negative NSCLC diagnosed between January 1, 2010, and December 31, 2015. The study was limited to patients who survived at least 6 weeks after surgery (ie, estimated median time to initiate adjuvant chemotherapy after surgery) to mitigate immortal time bias. Statistical analysis was performed from December 1, 2018, to February 29, 2020.

    Exposures  Adjuvant chemotherapy use vs observation, stratified according to the presence or absence of high-risk pathologic features (visceral pleural invasion, lymphovascular invasion, and high-grade histologic findings), sublobar surgery, and tumor size.

    Main Outcomes and Measures  The association of high-risk pathologic features with survival after adjuvant chemotherapy vs observation was evaluated using Cox proportional hazards regression models.

    Results  Overall, 50 814 eligible patients with NSCLC (27 365 women [53.9%]; mean [SD] age, 67.4 [9.5] years]) were identified, including 4220 (8.3%) who received adjuvant chemotherapy and 46 594 (91.7%) who did not receive adjuvant chemotherapy. Among patients with tumors 3 cm or smaller, chemotherapy was not associated with improved survival (hazard ratio [HR], 1.10; 95% CI, 0.96-1.26; P = .17). For patients with tumors larger than 3 cm to 4 cm, adjuvant chemotherapy was associated with a survival benefit among patients who underwent sublobar surgery (HR, 0.72; 95% CI, 0.56-0.93; P = .004). For tumors larger than 4 cm to 5 cm, a survival benefit was associated with adjuvant chemotherapy only in patients with at least 1 high-risk pathologic feature (HR, 0.67; 95% CI, 0.56-0.80; P = .02). For tumors larger than 5 cm, adjuvant chemotherapy was associated with a survival benefit irrespective of the presence of high-risk pathologic features (HR, 0.75; 95% CI, 0.61-0.91; P = .004).

    Conclusions and Relevance  In this cohort study, tumor size alone was not associated with improved efficacy of adjuvant chemotherapy in patients with early-stage (node-negative) NSCLC. High-risk clinicopathologic features and tumor size should be considered simultaneously when evaluating patients with early-stage NSCLC for adjuvant chemotherapy.

    ×